drugset / Trial / NCT00442533
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Phase 2/3
Completed
200 enrolled
Radio Isotope Therapy of America
CHI St. Luke's Health, Texas · collabExcel Diagnostic Imaging Clinics · collabRadiomedix, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
Timeline
- Start
- 2005-08
- Primary completion
- 2014-08-30
- Completion
- 2015-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INDIUM PENTETREOTIDE | Protein / enzyme biologic | 500 mbq | — |